Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare Risankizumab (Skyrizi) and Secukinumab (Cosentyx) — clinical data, side effects, and patient experiences.
Skyrizi · Biologic (IL-23 Inhibitor)
How it works
Humanized monoclonal antibody that selectively binds to the p19 subunit of IL-23, inhibiting IL-23-dependent inflammatory signalling.
Approved for
Cosentyx · Biologic (IL-17 Inhibitor)
How it works
Human monoclonal antibody that selectively binds to IL-17A, inhibiting its interaction with the IL-17 receptor to reduce inflammation.
Approved for
Estimated frequency (%) based on clinical trial data
No head-to-head clinical studies found for Risankizumab vs Secukinumab.
Risankizumab is a Biologic (IL-23 Inhibitor), while Secukinumab belongs to the Biologic (IL-17 Inhibitor) class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles.
Both medications are approved for Plaque Psoriasis, Psoriatic Arthritis. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.
Risankizumab carries 2 FDA warnings. Secukinumab carries 3 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.